Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 38c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q3 EPS of ($0.35), $0.38 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $19.57 million versus the consensus estimate of $12.32 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
• Hyperliquid Strategies to webcast fiscal year 2026 results